Prolia (Denosumab) Liver Function Impact: What Clinicians and Patients Need to Know

What Is Denosumab and How Does It Work?

Denosumab is a fully human monoclonal IgG2 antibody that binds with high affinity to RANK ligand (RANKL), blocking osteoclast formation, function, and survival. The FDA approved Prolia in June 2010 for postmenopausal women with osteoporosis at high fracture risk, and the indication has since expanded to include men with osteoporosis, glucocorticoid-induced osteoporosis, and bone loss associated with hormone-ablative therapy 1.

RANKL Biology Beyond Bone

RANKL is not expressed exclusively in bone. Hepatic stellate cells, Kupffer cells, and sinusoidal endothelial cells all express RANKL and its decoy receptor osteoprotegerin (OPG) to varying degrees 2. This expression pattern prompted early mechanistic questions about whether RANKL blockade could affect hepatic inflammation or fibrosis. Those questions remain scientifically interesting, but have not translated into clinical hepatotoxicity signals in human trials.

Clearance Pathway

Denosumab is a large-molecule biologic with a molecular weight of approximately 147 kDa. It is not metabolized by hepatic cytochrome P450 enzymes and does not undergo biliary excretion. Clearance occurs through the reticuloendothelial system via proteolytic degradation into small peptides and amino acids, the same route used by endogenous immunoglobulins 3. The half-life is approximately 25 to 28 days after a 60 mg subcutaneous dose, and steady-state exposure is reached after the second or third injection.

FREEDOM Trial: The Definitive Liver Safety Dataset

The FREEDOM trial is the primary source of denosumab liver safety data. Published in the New England Journal of Medicine in 2009, FREEDOM randomized 7,808 postmenopausal women aged 60 to 90 years with a bone mineral density T-score between -2.5 and -4.0 at the lumbar spine or total hip to subcutaneous denosumab 60 mg or placebo every 6 months for 36 months 3.

Fracture Efficacy

The primary endpoint results are well-established: denosumab reduced the risk of new vertebral fractures by 68% (7.2% placebo vs. 2.3% denosumab; P<0.001), hip fractures by 40% (1.2% vs. 0.7%; P=0.04), and nonvertebral fractures by 20% (8.0% vs. 6.5%; P=0.01) 3.

Hepatic Adverse Events in FREEDOM

The FREEDOM safety data did not identify liver function abnormalities as a distinguishing adverse event. The investigators reported that "serious adverse events occurred in 25.2% of women in the denosumab group and 25.4% in the placebo group" and that the overall adverse event profile was comparable between arms 3. Liver enzyme elevations meeting the threshold for clinical significance (greater than 3 times the upper limit of normal for ALT or AST) were not reported at a rate that differed meaningfully from placebo. No cases of drug-induced liver injury (DILI) meeting Hy's Law criteria were attributed to denosumab in the trial.

FREEDOM Extension: 10-Year Data

The long-term FREEDOM Extension study followed participants for up to 10 years of continuous denosumab exposure 4. By year 10 (N=2,626 completing the extension), the adverse event rate remained consistent with the placebo-controlled phase, and hepatic adverse events were not identified as an emerging safety concern with cumulative exposure. Clinicians often worry about long-term biologic exposure producing delayed organ toxicity; the 10-year dataset does not support that concern for the liver specifically.

FDA Labeling and Pharmacovigilance

The current FDA Prolia prescribing information (revised 2023) does not list hepatotoxicity, elevated liver enzymes, or liver failure in the Warnings and Precautions section 1. The labeled adverse reactions include hypocalcemia, serious infections (cellulitis, endocarditis), osteonecrosis of the jaw, atypical femoral fracture, and hypersensitivity reactions. Liver injury is absent from that list.

Post-Marketing Surveillance

The FDA Adverse Event Reporting System (FAERS) contains a small number of spontaneous reports associating denosumab with transaminase elevations, hepatitis, and jaundice. Spontaneous reports are inherently limited by confounding from concomitant medications, underlying disease, and reporting bias. A 2019 disproportionality analysis of FAERS data found that the reporting odds ratio for hepatotoxicity with denosumab was not statistically elevated compared to other osteoporosis drugs 5. The LiverTox database maintained by the National Institutes of Health classifies denosumab as a drug with "unlikely" likelihood of causing clinically apparent liver injury 6.

Hy's Law and DILI Assessment

Drug-induced liver injury requires meeting specific criteria. Hy's Law defines a concerning DILI signal as ALT or AST greater than 3 times the upper limit of normal combined with total bilirubin greater than 2 times the upper limit of normal, in the absence of other explanations. No published case series of denosumab-induced liver injury fulfilling Hy's Law has appeared in the peer-reviewed literature as of mid-2025. Isolated enzyme elevations without hyperbilirubinemia and without a clear temporal relationship to dosing have been reported but do not constitute a defined DILI syndrome.

RANKL/OPG Signaling in the Liver: Mechanistic Considerations

Understanding why denosumab does not appear to harm the liver requires appreciating the biology of RANKL in hepatic tissue.

RANKL in Hepatic Stellate Cells

Hepatic stellate cells express RANKL during activation, and OPG expression decreases during progressive hepatic fibrosis in animal models 2. In rodent models of nonalcoholic steatohepatitis (NASH), OPG administration attenuated stellate cell activation and reduced markers of fibrosis. This finding initially raised the question of whether exogenous RANKL blockade (via denosumab) might modulate hepatic fibrosis.

Translational Gap

The translational gap between rodent RANKL/OPG data and human hepatic outcomes with denosumab is substantial. Denosumab does not cross into hepatic sinusoids at pharmacologically relevant concentrations under standard dosing, and systemic RANKL suppression for 6-month intervals does not appear to alter circulating liver enzymes or bilirubin in clinical studies. No prospective human trial has been designed specifically to test whether denosumab modifies hepatic fibrosis or NASH progression.

Implications for Patients With Chronic Liver Disease

Patients with compensated cirrhosis or chronic hepatitis frequently develop osteoporosis secondary to reduced calcium absorption, vitamin D deficiency, and hypogonadism. These patients may have baseline elevations in AST, ALT, GGT, and alkaline phosphatase. Denosumab's non-hepatic clearance makes it an attractive option in this population because dose adjustment is not required for hepatic impairment, unlike bisphosphonates that depend on renal clearance. A 2021 retrospective cohort study (N=112 patients with cirrhosis-related osteoporosis) found that denosumab improved lumbar spine BMD by a mean of 4.3% at 12 months without clinically meaningful changes in Child-Pugh score or LFT values 7.

Monitoring Recommendations and Clinical Practice

No guideline currently mandates routine liver function test monitoring before or during denosumab therapy in patients without pre-existing hepatic disease. The American Association of Clinical Endocrinologists (AACE) 2020 clinical practice guidelines for osteoporosis management specify monitoring of calcium, phosphate, and 25-hydroxyvitamin D before initiating denosumab, but do not require a liver panel as standard of care 8.

Recommended Pre-Treatment Evaluation

A practical pre-treatment evaluation before starting Prolia in clinical practice includes:

• Serum calcium and albumin (to detect hypocalcemia risk)
• 25-hydroxyvitamin D (target at least 30 ng/mL before first dose)
• Serum creatinine and estimated GFR (hypocalcemia risk is higher with eGFR <30 mL/min/1.73 m2)
• Complete metabolic panel including LFTs if the patient has known or suspected hepatic disease, heavy alcohol use, or is on concurrent hepatotoxic medications

Routine LFT measurement in a patient with no liver disease history and no hepatotoxic co-medications is not supported by current evidence or guidelines. Ordering a baseline panel is reasonable for documentation purposes before a 10-year course of therapy, but the pre-test probability of a denosumab-related liver event is low enough that it should not delay therapy initiation.

Intra-Treatment Monitoring

Patients on denosumab do not require periodic liver function monitoring unless a new indication arises (new hepatotoxic co-medication, symptoms of hepatitis, unexplained jaundice, or new alcohol use disorder). The every-6-month injection visit is an appropriate touchpoint to review the medication list for hepatic interactions, but denosumab itself is not the concern.

When to Investigate Enzyme Elevations on Denosumab

If a patient on denosumab presents with elevated transaminases, the clinical approach mirrors standard DILI workup: exclude viral hepatitis, assess concomitant medications (statins, NSAIDs, acetaminophen), evaluate alcohol intake, obtain imaging to exclude biliary obstruction, and apply the RUCAM (Roussel Uclaf Causality Assessment Method) scale. Denosumab's long half-life means a temporal relationship is difficult to establish based on a single injection date. The causality score for denosumab will generally fall in the "unlikely" range given the absence of a rechallenge response and the lack of an immunoallergic signature.

Denosumab Compared to Other Osteoporosis Agents: Relative Hepatic Risk

Understanding denosumab's hepatic profile is more meaningful in the context of comparators.

Bisphosphonates

Oral bisphosphonates (alendronate, risedronate) undergo minimal hepatic metabolism and are renally cleared. Intravenous zoledronic acid (Reclast) is similarly non-hepatotoxic. Neither class carries a liver warning in FDA labeling. Denosumab and bisphosphonates are comparably low-risk from a hepatic standpoint.

Romosozumab

Romosozumab (Evenity), a sclerostin-inhibiting monoclonal antibody approved in 2019 for postmenopausal osteoporosis, shares the large-molecule, non-hepatic clearance profile of denosumab. The ARCH trial (N=4,093) did not identify hepatotoxicity as a safety signal for romosozumab 9.

Teriparatide and Abaloparatide

Teriparatide (Forteo) and abaloparatide (Tymlos), both PTH-analogue anabolic agents, carry no hepatotoxicity warnings. They are cleared primarily by enzymatic cleavage in peripheral tissue and have minimal hepatic involvement.

SERMs

Raloxifene (Evista) is metabolized hepatically via glucuronidation. While it does not cause hepatocellular injury, it is labeled for possible elevation of hepatic enzymes, and use in active liver disease is contraindicated. This makes denosumab a preferred option in women with liver disease who also need fracture protection.

Special Populations: Hepatic Impairment Dosing

Pharmacokinetic studies of denosumab have not identified a need for dose modification in hepatic impairment. The FDA prescribing information states no dedicated hepatic impairment pharmacokinetic study has been conducted, but given the non-hepatic clearance mechanism, dose adjustment is not expected to be necessary 1. Clinicians treating osteoporosis in patients with Child-Pugh Class A or B cirrhosis may use standard dosing (60 mg SC every 6 months) without adjustment. Class C cirrhosis data are absent from formal trials, and clinical judgment should be applied; the primary concern in severe cirrhosis is thrombocytopenia and infection risk, not hepatic drug toxicity from denosumab itself.

Managing the Denosumab Discontinuation Problem

One safety issue that does affect patients with liver disease indirectly is the rebound fracture risk after denosumab discontinuation. The FREEDOM Extension data showed that patients who stopped denosumab after 2 to 5 years experienced rapid bone mineral density loss within 12 months, and vertebral fracture rates rebounded to above pre-treatment baseline in some analyses 4.

For a patient with advanced liver disease who needs to stop denosumab because of a liver transplant evaluation (transplant programs often prefer to stabilize immunosuppressive burden before adding biologic therapy), bridging with a bisphosphonate infusion (zoledronic acid 5 mg IV) 6 months after the last denosumab dose is the current standard approach recommended in the 2022 Endocrine Society clinical practice guideline on osteoporosis in adults 10. The guideline states: "Sequential therapy with a bisphosphonate is recommended after denosumab discontinuation to prevent rapid bone loss and rebound fractures."

Drug Interactions Relevant to Patients With Liver Disease

Patients with chronic liver disease frequently take medications that are hepatically cleared or that cause DILI themselves. Denosumab's absence from the CYP450 system means it does not alter the pharmacokinetics of hepatically metabolized drugs. No dose adjustments for co-administered drugs are required on the basis of denosumab exposure.

Clinicians should, however, account for additive hypocalcemia risk when denosumab is combined with cinacalcet, loop diuretics, or antiepileptics that reduce calcium absorption. These interactions are unrelated to liver function but are clinically important in the post-transplant osteoporosis setting where many of these drugs are co-prescribed.

Emerging Research: RANKL, Liver Fibrosis, and MASLD

The field of metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD/NASH) has generated renewed interest in the RANKL/OPG axis. A 2022 study published in the Journal of Hepatology (N=341 patients with biopsy-proven MASLD) found that serum OPG levels were inversely correlated with fibrosis stage (Pearson r = -0.38; P<0.001), suggesting that the OPG/RANKL balance may track hepatic fibrosis progression 11. Whether denosumab, by mimicking OPG's effect on RANKL, could have a hepatoprotective role in MASLD is a testable hypothesis. No randomized controlled trial has been conducted on this question yet.

A prospective observational study registered at ClinicalTrials.gov (NCT05189509) is currently evaluating bone density and metabolic outcomes in patients with MASLD receiving denosumab vs. Bisphosphonate therapy for concomitant osteoporosis, with liver stiffness as a secondary endpoint. Results are expected by 2026. Until those data mature, denosumab should be prescribed for its approved indications only and not positioned as a liver-protective agent.